EP0694081A1 - $g(a)-N-ACETYLGALACTOSAMINIDASE RECOMBINEE ET ADNc CODANT CETTE ENZYME - Google Patents

$g(a)-N-ACETYLGALACTOSAMINIDASE RECOMBINEE ET ADNc CODANT CETTE ENZYME

Info

Publication number
EP0694081A1
EP0694081A1 EP94911730A EP94911730A EP0694081A1 EP 0694081 A1 EP0694081 A1 EP 0694081A1 EP 94911730 A EP94911730 A EP 94911730A EP 94911730 A EP94911730 A EP 94911730A EP 0694081 A1 EP0694081 A1 EP 0694081A1
Authority
EP
European Patent Office
Prior art keywords
acetylgalactosaminidase
leu
gly
enzyme
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94911730A
Other languages
German (de)
English (en)
Other versions
EP0694081A4 (fr
Inventor
Alex Zhu
Jack Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center Inc
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Publication of EP0694081A1 publication Critical patent/EP0694081A1/fr
Publication of EP0694081A4 publication Critical patent/EP0694081A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)

Definitions

  • This invention relates to a recombinant enzyme for use in the removal of type A antigens from the surface of cells in blood products, thereby converting certain sub-type A blood products to type 0 blood products and certain type AB blood products to type B blood products.
  • This invention further relates to methods of cloning and expressing said recombinant enzyme.
  • this invention is directed to a recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme, methods of cloning and expressing said recombinant ⁇ -N-acetylgalactosaminidase enzyme, and a method of removing type A antigens from the surface of cells in type A and AB blood products using said recombinant ⁇ -N-acetylgalactosaminidase enzyme by contacting said enzyme with blood products so as to remove the terminal moiety of the A-antigenic determinant from the surface of cells (for example, erythrocytes) in said blood products, while allowing the structure and function of the cells in the blood products to remain intact.
  • a recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme methods of cloning and expressing said recombinant ⁇ -N-acetylgalactosaminidase enzyme, and a method of removing type A anti
  • the recombinant ⁇ -N-acetylgalactosaminidase enzyme of this invention provides a readily available and cost-efficient enzyme which can be used in the removal of type A antigens from the surface of cells in type A and AB blood products.
  • Treatment of certain sub-type A blood products with the recombinant enzyme of this invention provides a source of cells free of the A antigen, which blood products are thereby rendered useful in transfusion therapy in the same manner of 0 type blood products.
  • blood products includes whole blood and cellular components derived from blood, including erythrocytes (red blood cells) and platelets.
  • erythrocytes red blood cells
  • platelets There are more than thirty blood group (or type) systems, one of the most important of which is the ABO system. This system is based on the presence or absence of antigens A and/or B. These antigens are found on the surface of erythrocytes and on the surface of all endothelial and most epithelial cells as well.
  • the major blood product used for transfusion is erythrocytes, which are red blood cells containing hemoglobin, the principal function of which is the transport of oxygen.
  • Blood of group A contains antigen A on its erythrocytes.
  • blood of group B contains antigen B on its erythrocytes.
  • Blood of group AB contains both antigens, and blood of group 0 contains neither antigen.
  • the blood group structures are glycoproteins or glycolipids and considerable work has been done to identify the specific structures making up the A and B determinants or antigens. It has been found that the blood group specificity is determined by the nature and linkage of monosaccharides at the ends of the carbohydrate chains.
  • the carbohydrate chains are attached to a peptide or lipid backbone which is embedded in the lipid bi-layer of the membrane of the cells.
  • the most important (immuno-dominant or immuno-determinant) sugar has been found to be N-acetylgalactosamine for the type A antigen and galactose for the type B antigen.
  • a ⁇ erythrocytes have more antigenic A sites, i.e., terminal N-acetylgalactosamine residues, than A int erythrocytes which in turn have more antigenic A sites than A_ erythrocytes.
  • the transferase enzymes responsible for the formation of A antigens differ biochemically • * • from each other in A.l, Am. t. and A2_ individuals. Some A antigens found in A. cells contain dual A antigenic sites.
  • Blood of group A contains antibodies to antigen B. Conversely, blood of group B contains antibodies to antigen A. Blood of group AB has neither antibody, and blood group O has both. A person whose blood contains either (or both) of the anti-A or anti-B antibodies cannot receive a transfusion of blood containing the corresponding incompatible antigen(s). If a person receives a transfusion of blood of an incompatible group, the blood transfusion recipient's antibodies coat the red blood cells of the transfused incompatible group and cause the transfused red blood cells to agglutinate, or stick together. Transfusion reactions and/or hemolysis (the destruction of red blood cells) may result therefrom.
  • transfusion blood type is cross-matched against the blood type of the transfusion recipient.
  • a blood type A recipient can be safely transfused with type A blood which contains compatible antigens.
  • type 0 blood contains no A or B antigens, it can be transfused into any recipient with any blood type, i.e., recipients with blood types A, B, AB or 0.
  • type 0 blood is considered "universal", and may be used for all transfusions.
  • t and A_ erythrocytes to erythrocytes of the H antigen type which is described in the '627 Patent includes the steps of equilibrating certain sub-type A or AB erythrocytes, contacting the equilibrated erythrocytes with purified chicken liver ⁇ -N-acetylgalactosaminidase enzyme for a period sufficient to convert the A antigen to the H antigen, removing the enzyme from the erythrocytes and re-equilibrating the erythrocytes.
  • ⁇ -N-acetylgalactosaminidase obtained from an avian liver (specifically, chicken liver) source was found to have superior activity in respect of enzymatic conversion or cleavage of A antigenic sites.
  • a recombinant, cloned enzyme allows for specific protein sequence modifications, which can be introduced to generate an enzyme with optimized specific activity, substrate specificity and pH range.
  • ⁇ -N-acetylgalactosaminidase enzymes are characterized (and thereby named) by their ability to cleave N-acetylgalactosamine sugar groups. In isolating or identifying these enzymes, their activity is assessed in the laboratory by evaluating cleavage of synthetic substrates which mimic the sugar groups cleaved by the enzymes, with p-nitrophenylglycopyranoside derivatives of the target sugar groups being commonly used.
  • these synthetic substrates are simple structurally and small-sized and mimic only a portion of the natural glycoproteins and glycolipid structures which are of primary concern, those being the A antigens on the surface of cells.
  • a natural glycolipid substrate originally isolated from sheep erythrocytes, is the Forsmann antigen (globopentaglycosylceramide) .
  • the Forsmann antigen substrate appropriately mimics the natural A antigen glycolipid structures and is therefore utilized to predict the activity of ⁇ -N-acetylgalactosaminidase enzymes against the A antigen substrate.
  • Isolated Forsmann antigen glycolipids have been shown to inhibit hemolysis of sheep red cells by immune rabbit anti-A serum in the presence of serum com lement.
  • ⁇ -N-acetylgalactosaminindase enzyme has been isolated from a number of sources besides chicken liver 5 (described above), including bacteria, mollusks, earthworms, and human liver.
  • the human ⁇ -N-acetylgalactosaminidase enzyme has been purified, sequenced, cloned and expressed.
  • PCT Application No. WO 92/07936 discloses the cloning and expression of the cDNA which encodes human ⁇ -N-acetylgalacto ⁇ aminidase.
  • substrate specificity measures the binding constant or affinity of an enzyme for a particular substrate. The lower a Km value, the more tightly an enzyme binds its substrate.
  • the velocity of an enzyme cleavage reaction is measured in the Vmax, the reaction rate at a saturating concentration of substrate. A higher Vmax indicates a faster cleavage rate.
  • Vmax/Km is a measure of the overall efficiency of an enzyme in reacting with (cleaving) a given substrate. A higher Vmax/Km indicates greater enzyme efficiency.
  • the enzyme For successful and clinically applicable removal of A antigens from the surface of cells, the enzyme must be sufficiently active at or above a pH at which the cells being treated can be maintained. The procedure described in the '627 patent calls for treatment of cells at or above a pH of 5.6. Therefore, the pH optimum of an appropriate enzyme must still provide reasonable enzyme activity at this pH.
  • Vmax/Km, Vmax, Km and pH optimum are reported for the human ⁇ -N-acetylgalactosaminidase enzyme in "Studies on Human Liver ⁇ -galactosidases” , by Dean et al. in The Journal of Biological Chemistry, Vol. 254, No. 20, pages 10001-10005 (1979).
  • the Vmax/Km value for the Forsmann antigen of human ⁇ -N-acetylgalactosaminidase is 0.46, as compared to a Vmax/Km value of 5.0 for the chicken liver enzyme, indicating an approximately ten-fold difference in efficiency.
  • the Km is lower and the Vmax is higher for the chicken liver enzyme, compared to the human enzyme.
  • human ⁇ -N-acetylgalactosaminidase has a pH optimum for the Forsmann antigen of 3.9, compared to 4.7 for chicken liver ⁇ -N-acetylgalactosaminida ⁇ e. By all of these enzyme characteristics, human ⁇ -N-acetylgalactosaminidase enzyme is not suitable for removal of A antigens, particularly when compared to the chicken liver enzyme.
  • Figure 1 represents a diagram of the strategy used to clone and sequence the chicken liver ⁇ -N-acetylgalactosaminidase cDNA
  • Figure 2 represents the nucleic acid sequence and the deduced amino acid sequence of the chicken liver ⁇ -N-acetylgalactosaminidase cDNA clone;
  • Figure 3 represents the expression of chicken liver ⁇ -N-acetylgalactosaminidase in bacteria and rabbit reticulocyte lysate as shown by Western blot;
  • Figure 4 represents a homology comparison between ⁇ -N-acetylgalactosaminidases and ⁇ -galactosidases;
  • Figure 5 represents the expression of chicken liver ⁇ -N-acetylgalactosaminidase in yeast as shown by Western blot.
  • This invention is directed to a recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme, which enzyme has a molecular weight of about 45 kDa, is i munoreactive with an antibody specific for chicken liver ⁇ -N-acetylgalactosaminidase, and also has about 80% amino acid sequence homology with human ⁇ -N-acetylgalactosaminidase enzyme.
  • the recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme of this invention has the amino acid sequence depicted in Figure 2, from amino acid number 1 to amino acid number 406.
  • This invention is further directed to methods of cloning and expressing the recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme, and to a method of using said enzyme to remove A antigens from the surface of cells in blood products so as to convert said blood products of certain A sub-types to type O, thereby rendering said blood products universal for use in transfusion therapy.
  • This invention is directed to a recombinant enzyme for use in the removal of type A antigens from the surface of cells in blood products, thereby converting certain sub-type A blood products to type 0 blood products and certain sub-type AB blood products to type B blood products .
  • the recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme of this invention has a molecular weight of about 45 kDa and is immunoreactive with an antibody specific for chicken liver ⁇ -N- acetylgalactosaminidase.
  • the recombinant enzyme of this invention has about 80% amino acid sequence homology with human ⁇ -N-acetylgalactosaminidase enzyme.
  • the recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme of this invention has the following nucleic acid and deduced amino acid sequence:
  • the recombinant chicken liver ⁇ -N- acetylgalactosaminidase enzyme of this invention can be cloned and expressed so that it is readily available for use in the removal of A antigens from the surface of cells in blood products.
  • the enzyme of this invention can be cloned and expressed by screening a chicken liver cDNA library to obtain the cDNA sequence which encodes the chicken liver ⁇ -N-acetylgalactosaminidase, sequencing the encoding cDNA once it is determined, cloning the encoding cDNA and expressing ⁇ -N-acetylgalactosaminidase from the cloned encoding cDNA.
  • This may be performed by obtaining an amplified human ⁇ -N-acetylgalactosaminidase fragment capable of use as a screening probe, screening a chicken liver cDNA library, such as the one described hereinabove, using the amplified human ⁇ -N-acetylgalactosaminidase fragment as a probe so as to obtain the cDNA sequence of the chicken liver cDNA library which encodes chicken liver ⁇ -N-acetylgalactosaminidase, sequencing the encoding DNA, cloning the encoding DNA and expressing chicken liver ⁇ -N-acetylgalactosaminidase enzyme from the cloned encoding cDNA.
  • screening can be performed using antibodies which recognize chicken liver ⁇ -N-acetylgalactosaminidase.
  • expression vectors containing the chicken liver ⁇ -N-acetylgalactosaminidase coding sequence can be used to construct expression vectors containing the chicken liver ⁇ -N-acetylgalactosaminidase coding sequence, with appropriate transcriptional/translational signals for expression of the enzyme in the corresponding expression systems.
  • Appropriate organisms, cell types and expression systems include: cell-free systems such as a rabbit reticulocyte lysate system, prokaryotic bacteria, such as E. coli, eukaryotic cells, such as yeast, insect cells, mammalian cells (including human hepatocytes or Chinese hamster ovary (CHO) cells), plant cells or systems, and animal systems including oocytes and transgenic animals.
  • the entire chicken liver ⁇ -N-acetylgalactosaminidase coding sequence or functional fragments of functional equivalents thereof may be used to construct the above expression vectors for production of functionally active enzyme in the corresponding expression system. Due to the degeneracy of the DNA code, it is anticipated that other DNA sequences which encode substantially the same amino acid sequence may be used. Additionally, changes to the DNA coding sequence which alter the amino acid sequence of the chicken liver ⁇ -N-acetylgalactosaminidase enzyme may be introduced which result in the expression of functionally active enzyme. In particular, amino acid substitutions may be introduced which are based on similarity to the replaced amino acids, particularly with regard to the charge, polarity, hydrophobicity, hydrophilicity, and size of the side chains of the amino acids.
  • Sub-type A antigens can be removed from the surface of erythrocytes by contacting the erythrocytes with the recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme of this invention for a period of time sufficient to remove the A antigens from the surface of the erythrocytes.
  • Chicken liver ⁇ -N-acetylgalactosaminidase was purified to homogeneity.
  • the enzyme was a glycoprotein with a molecular weight of 80 kDa, and was dissociated into two identical subunits at pH 7.5. Its optimal pH for cleavage of the synthetic p-nitrophenyl- ⁇ -N-acetylgalactosaminyl- pyranoside substrate was 3.65 and the activity dropped sharply when the pH was raised above 7.
  • the N-terminal sequence obtained from the purified chicken liver ⁇ -N-acetylgalactosaminidase showed a strong homology with the corresponding sequence deduced from the human ⁇ -N-acetylgalactosaminidase cDNA clone described in Tsuji et al. , and Wang et al.
  • two oligonucleotides, corresponding to nucleotides 688 to 705 and 1219 to 1236 of the human ⁇ -N-acetylgalactosaminidase sequence published by Wang, et al. were synthesized.
  • the specific cDNA was made from the downstream (C-terminal) oligonucleotide.
  • a DNA fragment corresponding to human ⁇ -N-acetylgalactosaminidase residues from 688 to 1236 was amplified from the cDNA by the hot-start PCR technique.
  • the PCR reaction mixture was preheated at 95°C for 5 minutes and maintained at 80°C while Taq DNA polymerase (Promega) was added to reduce the possible non-specific annealing at lower temperature. 35 cycles of amplification was then carried out as follows: 94°C for 1 minute, 50 ⁇ C for 2 minutes and 72 ⁇ C for 3 minutes.
  • the same conditions for PCR were applied in all of the following experiments.
  • the PCR-amplified fragment was then used as a radioactively-labeled probe in the screening of a chicken liver cDNA library (Stratagene) based on homology hybridization.
  • the filters containing the library were hybridized with the probe overnight at 42°C in a solution of 50% formamide, 5XSSPE, 5XDenhardt's, 0.1% SDS and 0.1 mg/ml salmon sperm DNA.
  • the filters were then washed as follows:
  • the filters were autoradiographed overnight at -70 ⁇ C.
  • the positive clones were picked up for the second-round screening following the same procedure. In total, three consecutive screenings were carried out in order to obtain a well-isolated positive clone.
  • the library was rescreened by using the 1.9 kb cDNA clone as a probe. However, no positive clone was identified by this approach.
  • the upstream cDNA sequence was then obtained by applying multiple amplification (the nested PCR technique) of. a second chicken liver cDNA library (Clontech).
  • Figure 1 represents a diagram of the strategy used to clone and sequence the chicken liver ⁇ -N-acetylgalactosaminidase cDNA.
  • the cDNA encoding chicken liver ⁇ -N-acetylgalactosaminidase contained a 1.2 kb coding region (slashed area) and a 1.2 kb 3' untranslated region.
  • the arrows at the bottom of the diagram indicate the sequencing strategy.
  • CLl, CL2 and CL3 are oligonucleotides used as primers for the nested PCR.
  • CLl and CL2 are located at position 924-941 nt and 736-753 nt, respectively (see Figure 2).
  • the oligonucleotide CL3 [5'-CTGGAGAAC(T)GGA(GC)CTGGCT(CA)CG] was designed taking into account chicken codon usage and "best guess".
  • the whole cDNA library was used as a template in the presence of one specific primer (CLl) (see Figure 1) and one universal primer derived from the library vector (5'-CTGGTAATGGTAGCGACC) .
  • CLl specific primer
  • 5'-CTGGTAATGGTAGCGACC universal primer derived from the library vector
  • a small aliquot from the above reaction was directly taken for the second-round amplification with a different set of primers.
  • the primer CL2 had the sequence located upstream of CLl ( Figure 1) and the second primer, CL3, was designed based on the N-terminal amino acid sequence from purified chicken liver ⁇ -N-acetylgalactosaminidase (see Figure 1).
  • a 750 bp fragment was sequenced to eliminate any possible PCR artifacts.
  • the Cloned DNA Encodes Chicken Liver ⁇ -N-Acetylqalactosaminidase
  • Figure 2 represents the nucleic acid sequence and deduced amino acid sequence of the chicken liver ⁇ -N-acetylgalactosaminidase cDNA clone.
  • the underlined regions in Figure 2 match sequences obtained from the N-terminus and CNBr-derived fragments of enzyme purified from chicken liver.
  • the first 3 nucleotides, ATG, were added during subcloning to serve as the translational initiation codon for protein expression.
  • the polyadenylation signal (AATAAA) at positions 2299-2304 nt is double-underlined.
  • the boxed sequence indicates potential sites for N-glycosylation.
  • the mature protein of 405 amino acids has a molecular mass of about 45 kDa, consistent with that of the purified enzyme estimated by SDS-PAGE. Due to the cloning approach applied, the sequence at the 5' end of the cDNA corresponded to the N-terminal sequence of the mature enzyme isolated from chicken liver.
  • the sequence from 1 to 1260 nucleotides which contained the coding region for chicken liver ⁇ -N-acetylgalactosaminidase was subcloned into the vector PCR-II (Invitrogen) in such an orientation that the T7 promoter was located upstream of the insert. Since the N-terminus of the mature protein started with leucine, a translational initiation codon, ATG, was added during the subcloning construction. The construct was then used as a template in a transcription-translation coupled system, TNT system (Promega), for protein expression according to the procedure recommended by the manufacturer.
  • TNT system Promega
  • the cDNA was subcloned into the EcoRI site of the pTrcHis vector (Invitrogen) for expression in E. coli. Because of the sequence in the vector, the expressed enzyme contained a polyhistidine-tag in its N-terminus, which permitted one step purification by affinity chromatography from crude cell lysates.
  • Figure 3 represents the expression of chicken liver ⁇ -N-acetylgalactosaminidase in bacteria and rabbit reticulocyte lysate as shown by Western blotting. Lane 1 through lane 4 demonstrate the results of expression in a rabbit reticulocyte lysate. The expression was carried out in
  • Sequences I and II are of ⁇ -N-acetylgalactosaminidases from chicken liver and human placenta, respectively.
  • Sequences III, IV, V and VI represent ⁇ -galactosidase from human, yeast, Cyamopsis tetraqonoloba and Aspergi1lus niger, respectively.
  • Sequences IV and VI are truncated at the C-terminus, as indicated by **. Identical or conservatively substituted amino acid residues (five out of six or more) among the aligned protein sequences are boxed. The numbers above the sequences indicate the relative position of each peptide sequence.
  • the deduced amino acid sequence from chicken liver ⁇ -N-acetylgalactosaminidase cDNA shows approximately 80% homology with the human ⁇ -N-acetylgalactosaminidase as determined by PROSIS. This homology indicates the relatedness of the human and chicken liver enzymes, despite the differences in the specific characteristics of the enzymes, particularly with regard to cleavage of the Forsmann antigen, as has already been described. Also, polyclonal antibodies raised against chicken liver ⁇ -N-acetylgalactosaminidase enzyme do not cross react with the hum ⁇ n enzyme. The specific amino acids responsible for these differences remain to be elucidated.
  • Yamachi et al . (1990) reported that a human ⁇ -N-acetylgalactosaminidase cDNA with an insertion of 70bp at the position corresponding to number 376 in Figure 4 was not enzymatically active in a transient expression study in COS cells. The data suggests that the open reading frame shift caused by this insertion in the C-terminal portion of the molecule is responsible for the loss of enzymatic activity, indicating that amino acids in the C-terminal region may be essential for ⁇ -N-acetylgalactosaminidase enzyme activity.
  • the first 48 nucleotides of human ⁇ -N-acetylgalactosaminidase cDNA (Wang, et al. 1990) which correspond to the signal peptide sequence, were linked to the cloned chicken liver ⁇ -N-acetylgalactosaminidase coding region by PCR.
  • the PCR amplified product was subcloned directly into the vector PCR-II (Invitrogen).
  • Two EcoRl sites flanking the insert were used to subclone the entire ⁇ -N-acetylgalactosaminidase cDNA into the yeast expression vector pYES2 (Invitrogen) in such an orientation that the GAL 1 promoter was located upstream of the insert.
  • the GAL 1 promoter provides expression of the inserted cDNA clone under galactose inducing growth conditions in yeast.
  • the yeast vector constructs were transformed into the yeast strain, INVSCI (Invitrogen) using standard procedures.
  • INVSCI Invitrogen
  • the total proteins from cell extract and culture supernatant were prepared and separated by 12% SDS-PAGE and a Western blot performed (by standard conditions) using the polyclonal antibody raised against purified chicken liver ⁇ -N-acetylgalactosaminidase.
  • the transformed yeast cells were grown in medium without uracil (Bio 101, Inc.). After 0.2% galactose induction, the cells were centrifuged and protein extracts were prepared using glass bead disruption. The secreted proteins in the culture supernatant were concentrated with a Centricon-30 (Amicon Division, W.R. Grace & Co.). The Western blot results are depicted in Figure 5.
  • Lanes 1 and 8 of Figure 5 show the ⁇ -N-acetylgalactosaminidase purified from chicken liver.
  • Lane 2 through lane 4 are cell extracts from the yeast transformed with three different pYES2 constructs: the vector alone (lane 2), chicken liver ⁇ -N-acetylgalactosaminidase cDNA coding region (lane 3), and the coding region plus signal sequence (lane 4).
  • Lane 5 is the culture supernatant from transformed yeast used in Lane 4.
  • Lane 7 shows the molecular weight standard. As shown in Figure 5, while the protein without signal peptide was expressed within yeast cells (lane 3), the protein with a signal peptide sequence was predominantly secreted into the media (lane 5).
  • the expressed enzyme eluted from the column demonstrates activity toward the synthetic substrate p-nitrophenyl- ⁇ -N-acetylgalactosaminylpyranoside at pH 3.6. Heavily glycosylated enzyme did not bind to the affinity column and showed no activity against synthetic substrate. All the data taken together demonstrate production, secretion and purification of enzymatically active chicken liver ⁇ -N-acetylgalactosaminidase in yeast cells.
  • NAME/KEY chicken liver ⁇ -N- acetylgalactosaminidase
  • NAME/KEY chicken liver ⁇ -N- acetylgalactosaminidase
  • TITLE Fabry Disease: Isolation of a cDNA Clone Encoding Human ⁇ -Galactosidase A
  • Trp Pro Phe Gin Lys Pro Asn Tyr Thr Glu He Arg Gin Tyr Cys Asn 224 His Trp Arg Asn Phe Ala Asp He Asp Asp Ser Trp Lys Ser He Lys 240
  • ORGANISM yeast Saccharomyces cerevisiae
  • NAME/KEY yeast ⁇ -galactosidase
  • MOLECULE TYPE (A) DESCRIPTION: cDNA to mRNA
  • MOLECULE TYPE (A) DESCRIPTION: cDNA to mRNA

Abstract

Cette invention se rapporte à une enzyme recombinée destinée à être utilisée dans l'élimination des antigènes A de la surface de cellules dans des produits sanguins. Spécifiquement, cette invention concerne une α-N-acétylgalactosaminidase recombinée issue du foie de poulets, des procédés de clonage et d'expression de ladite α-N-acétylgalactosaminidase recombinée et un procédé d'élimination des antigènes A de la surface de cellules de produits sanguins utilisant ladite α-N-acétylgalactosaminidase recombinée.
EP94911730A 1993-03-26 1994-03-28 -g(a)-N-ACETYLGALACTOSAMINIDASE RECOMBINEE ET ADNc CODANT CETTE ENZYME Ceased EP0694081A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3724893A 1993-03-26 1993-03-26
PCT/US1994/003338 WO1994023070A1 (fr) 1993-03-26 1994-03-28 α-N-ACETYLGALACTOSAMINIDASE RECOMBINEE ET ADNc CODANT CETTE ENZYME
US37248 1998-03-09

Publications (2)

Publication Number Publication Date
EP0694081A1 true EP0694081A1 (fr) 1996-01-31
EP0694081A4 EP0694081A4 (fr) 1998-07-15

Family

ID=21893290

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94911730A Ceased EP0694081A4 (fr) 1993-03-26 1994-03-28 -g(a)-N-ACETYLGALACTOSAMINIDASE RECOMBINEE ET ADNc CODANT CETTE ENZYME

Country Status (5)

Country Link
EP (1) EP0694081A4 (fr)
JP (1) JPH08508406A (fr)
AU (1) AU688310B2 (fr)
CA (1) CA2159083C (fr)
WO (1) WO1994023070A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7719696A (en) * 1995-10-18 1997-05-07 New York Blood Center, Inc., The Recombinant alpha-n-acetylgalactosaminidase enzyme
WO2000063351A2 (fr) * 1999-04-21 2000-10-26 Incyte Genomics, Inc. Enzymes modifiant les hydrates de carbone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009121A1 (fr) * 1992-10-22 1994-04-28 The New York Blood Center, Inc. Preparation d'une enzyme destinee a la conversion d'erythrocytes de sous-type a et ab
WO1994011518A2 (fr) * 1992-11-18 1994-05-26 Genencor International, Inc. Procedes de conversion de groupes sanguins a, ab et b en groupe sanguin o
WO1994012628A1 (fr) * 1992-11-30 1994-06-09 The Mount Sinai School Of Medicine Of The City University Of New York Clonage et expression d'alpha-galactosidase a biologiquement active

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609627A (en) * 1983-08-01 1986-09-02 New York Blood Center, Inc. Enzymatic conversion of certain sub-type A and AB erythrocytes
US5382524A (en) * 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009121A1 (fr) * 1992-10-22 1994-04-28 The New York Blood Center, Inc. Preparation d'une enzyme destinee a la conversion d'erythrocytes de sous-type a et ab
WO1994011518A2 (fr) * 1992-11-18 1994-05-26 Genencor International, Inc. Procedes de conversion de groupes sanguins a, ab et b en groupe sanguin o
WO1994012628A1 (fr) * 1992-11-30 1994-06-09 The Mount Sinai School Of Medicine Of The City University Of New York Clonage et expression d'alpha-galactosidase a biologiquement active

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOGAN, EDWARD L. ET AL: "Membrane glycosphingolipids in chicken muscular dystrophy" ADV. EXP. MED. BIOL. (1982), 152, 273-8 CODEN: AEMBAP;ISSN: 0065-2598, 1982, XP002055398 *
J. HATA ET AL.: "Purification and characterization of N-acetyl-alpha-D-galactosaminidase from Gallus domesticus" BIOCHEMISTRY INTERNATIONAL, vol. 28, no. 1, October 1992, pages 77-86, XP002055397 *
See also references of WO9423070A1 *

Also Published As

Publication number Publication date
AU6417594A (en) 1994-10-24
EP0694081A4 (fr) 1998-07-15
JPH08508406A (ja) 1996-09-10
AU688310B2 (en) 1998-03-12
CA2159083A1 (fr) 1994-10-13
CA2159083C (fr) 2002-07-02
WO1994023070A1 (fr) 1994-10-13

Similar Documents

Publication Publication Date Title
Connell et al. Molecular cloning, primary structure, and orientation of the vertebrate photoreceptor cell protein peripherin in the rod outer segment disk membrane
Yamamoto et al. Cloning and expression of a marine bacterial β-galactoside α2, 6-sialyltransferase gene from Photobacterium damsela JT0160
US5326857A (en) ABO genotyping
TW302369B (fr)
US6291219B1 (en) α1-6 fucosyltransferase
US5714376A (en) Heparinase gene from flavobacterium heparinum
EP0739983A2 (fr) Gène codant pour lacto-N-biosidase
KR100541202B1 (ko) 엔도글리코세라미다아제 액티베이터를 코딩하는 유전자
US6228631B1 (en) Recombinant α-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
AU688310B2 (en) Recombinant alpha-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
AU703180B2 (en) Recombinant alpha-galactosidase enzyme and cDNA encoding said enzyme
WO1996023869A1 (fr) ENZYME α-GALACTOSIDASE RECOMBINEE
JPH10313867A (ja) グルクロン酸転移酵素をコードするｄｎａ
WO1997014786A1 (fr) α-N-ACETYLGALACTOSAMINIDASE RECOMBINEE
US6764844B1 (en) DNA sequence encoding a novel glucuronyl C5-epimerase
Li et al. Cancer-associated lactate dehydrogenase is a tyrosylphosphorylated form of human LDH-A, skeletal muscle isoenzyme
US20030129652A1 (en) Human sperm specific lysozyme-like proteins
US6395477B1 (en) Human potassium channel polynucleotide and polypeptides and uses thereof
Zhou-Chou et al. Expression, purification and characterisation of secreted recombinant glycoprotein PsA in Dictyostelium discoideum
US20020115141A1 (en) Method for improved production of cyanophycin and secondary products thereof
JPH11137247A (ja) β１，４−ガラクトース転移酵素の製造法
JPH11253163A (ja) シアル酸転移酵素の製造法
WO2001053487A2 (fr) Proteines du type lisozyme, specifiques du sperme
JPH1189574A (ja) β−Ｎ−アセチルガラクトサミニダーゼ遺伝子
JPH05199893A (ja) ヒツジｌｆａ−３およびｔｍ領域欠失型ｌｆａ−３タンパク質

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980526

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990901

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020616